Table 2.
Effect of in vitro SjGCP inhibition on parasite pairing at 7 days post‐siRNA treatment
| Group | Subgroup | Number of parasites (mean ± SD) | Number of pairs (mean ± SD) | Percent inhibitiona |
|---|---|---|---|---|
| Control* | Untreated | 108 ± 10 | 12 ± 4 | 0 |
| Irrelevant, 50 nm | 99 ± 15 | 10 ± 3 | 0 | |
| Irrelevant, 200 nm | 94 ± 18 | 8 ± 3 | 0 | |
| Test | SjGCP s1, 50 nm | 105 ± 11 | 4 ± 2 | 60 |
| SjGCP s1, 200 nm | 86 ± 17 | 0 | 100 | |
| SjGCP s2, 50 nm | 101 ± 8 | 6 ± 4 | 40 | |
| SjGCP s2, 200 nm | 79 ± 20 | 0 | 100 | |
| SjGCP s3, 50 nm | 110 ± 5 | 8 ± 4 | 20 | |
| SjGCP s3, 200 nm | 104 ± 9 | 4 ± 2 | 60 |
For statistical average of the worm number/number of pairing in untreated, irrelevant 50 nm and irrelevant 200 nm was used as the control values (consideration as 100% uninhibition).
Calculated by multiplying (×100) the ratio of the average number of pairing in SjGCP siRNA‐treated groups to the control (statistical mean of the number of pairing in untreated, irrelevant 50 nm and irrelevant 200 nm siRNA‐treated) groups. The value obtained was subtracted from 100. Data are expressed as the mean ± SD of three independent experiments.
This article is being made freely available through PubMed Central as part of the COVID-19 public health emergency response. It can be used for unrestricted research re-use and analysis in any form or by any means with acknowledgement of the original source, for the duration of the public health emergency.